alkylation

(redirected from alkylating agent)
Also found in: Dictionary, Thesaurus, Medical, Legal, Financial, Wikipedia.

alkylation

[‚al·kə′lā·shən]
(chemical engineering)
A refinery process for chemically combining isoparaffin with olefin hydrocarbons.
(organic chemistry)
A chemical process in which an alkyl radical is introduced into an organic compound by substitution or addition.
References in periodicals archive ?
According to previous researches, alkylating agents, specifically busulfan and melphalan, are associated with the development of FNH when administered prior to bone marrow transplant due to SOS [7].
These three patients with multiple myeloma and ESRD were treated with alkylating agents and autologous HSCT; each had prolonged infection and developed severe SOS in case 1, very severe SOS in case 2, and moderate SOS in case 3 based on proposed grading of SOS severity by EBMT criteria [1] (Table 1).
We have synthesized three new pyrroloimidazole by 1, 3 dipolar cycloaddition by using new alkylating agent isopropyl bromoacetate with sulfur activated dipolarophiles.
Second, a predictably poor alkylating agent, isopropyl iodide, gave only N-isopropyl-2-phenylindole in low yield when a normal quantity (25% mole) of TEBAC was used in conjunction with 1 eq.
Moreover, it is known to improve chemotherapeutic efficacy of certain alkylating agents [28].
Chlorambucil is an alkylating agent with immunosuppressant and antineoplastic properties.
The compounds tested thus far include N-methyl-N'-nitro-nitrosoguanidine (an alkylating agent similar to methyl methane sulfonate) and cadmium (a toxic metal found in tap water).
A patent -protected, potent cytotoxic drug and intraveneous formulation of the alkylating agent busulfan.
ESP Pharma, Inc., Edison, NJ, announced it has acquired from Orphan Medical, Inc., Minnetonka, MN, worldwide rights to Busulfex Injection, an intravenous formulation of the alkylating agent busulfan, a drug often used in bone marrow transplantation.
(b) A derivative [Hcy-acetylbenzoic acid (Hcy-ABA)] is formed by reacting with the alkylating agent p-(2-chloroacetyl)benzoic acid phosphate (CABA-phosphate); and
Cisplatin is a heavy, metal alkylating agent used in treating testicular, ovarian, Hodgkins and non-Hodgkins lymphomas, sarcomas, bladder, lung, esophagus, cervix and prostate cancers.
This particular alkylating agent induces N7-methylguanine and N3-methyladenine at about 86% and 10% of total alkylation, respectively.